A chance for the US regulator to show its teeth, at Amag’s expense
An advisory panel votes to pull Amag’s Makena from the market, but will the US regulator follow through?
Go or no go? Merck, Regeneron and Alexion await US expansion
Approvals for new uses of old drugs should far outweigh nods for novel projects in June.
As takeover hopes build, 2018 provides a low bar to beat
Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.